The role of corticosteroids in the treatment of Kawasaki disease

References

• Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974 Sep;54(3):271–276. PubMed PMID: 4153258; eng.
   PubMed Web of Science ®Google Scholar
• Huang YH, Lin KM, Ho SC, et al. Increased incidence of Kawasaki disease in Taiwan in recent years: A 15 years nationwide population-based cohort study. Front Pediatr. 2019;7:121. PubMed PMID: 30984731; PubMed Central PMCID: PMCPMC6450208. eng.
   PubMed Web of Science ®Google Scholar
• Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984 Nov 10;2(8411):1055–1058. PubMed PMID: 6209513; eng.
   PubMed Web of Science ®Google Scholar
• Levin M. Steroids for Kawasaki disease: the devil is in the detail. Heart. 2013 Jan;99(2):69–70. PubMed PMID: 23086972; eng.
   PubMed Web of Science ®Google Scholar
• Furusho K, Sato K, Soeda T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1983 Dec 10;2(8363):1359. PubMed PMID: 6196587; eng.
   PubMed Web of Science ®Google Scholar
• McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American heart association. Circulation. 2017 Apr 25;135(17):e927–e999. PubMed PMID: 28356445; eng.
   PubMed Web of Science ®Google Scholar
• Huang YH, Chen KD, Lo MH, et al. Decreased steroid hormone receptor NR4A2 expression in Kawasaki disease before IVIG treatment. Front Pediatr. 2019;7:7. PubMed PMID: 30778379; PubMed Central PMCID: PMCPMC6369254. eng.
   PubMed Web of Science ®Google Scholar
• Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature. 2010 Jun 17;465(7300):937–941. PubMed PMID: 20559388; PubMed Central PMCID: PMCPMC2964153. eng.
   PubMed Web of Science ®Google Scholar
• Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr. 2003 Sep;143(3):363–367. PubMed PMID: 14517521; eng.
   PubMed Web of Science ®Google Scholar
• Makata H, Ichiyama T, Uchi R, et al. Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease. Naunyn-Schmiedeberg’s Arch Pharmacol. 2006 Aug;373(5):325–332. PubMed PMID: 16896803; eng.
   Google Scholar
• Wang J, Zhou N, Wu S, et al. Changes in 11beta-hydroxysteroid dehydrogenase and glucocorticoid receptor expression in Kawasaki disease. Korean Circ J. 2017 May;47(3):377–382. PubMed PMID: 28567088; PubMed Central PMCID: PMCPMC5449532. eng.
   PubMed Web of Science ®Google Scholar
• Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995 Dec;96(6):1057–1061. PubMed PMID: 7491221; eng.
   PubMed Web of Science ®Google Scholar
• Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979 Feb;63(2):175–179. PubMed PMID: 440805; eng.
   PubMed Web of Science ®Google Scholar
• Millar K, Manlhiot C, Yeung RS, et al. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression. Int J Cardiol. 2012 Jan 12;154(1):9–13. PubMed PMID: 20851480; eng.
   PubMed Web of Science ®Google Scholar
• Dominguez SR, Birkholz M, Anderson MS, et al. Diagnostic and treatment trends in children with Kawasaki disease in the United States, 2006–2015. Pediatr Infect Dis J. 2019 Oct;38(10):1010–1014. PubMed PMID: 31365480; eng.
   PubMedGoogle Scholar
• Fernandez-Cooke E, Barrios Tascon A, Sanchez-Manubens J, et al. Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011–2016): KAWA-RACE study group. PloS One. 2019;14(5):e0215665. PubMed PMID: 31107862; PubMed Central PMCID: PMCPMC6527399. eng.
   PubMed Web of Science ®Google Scholar
• Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. PubMed PMID: 17664228; eng Lupus. 2007;16(6):387–393.
   PubMed Web of Science ®Google Scholar
• Franchin G, Diamond B. Pulse steroids: how much is enough? Autoimmun Rev. 2006 Feb;5(2):111–113. PubMed PMID: 16431338; eng.
   PubMed Web of Science ®Google Scholar
• Ciccone A, Beretta S, Brusaferri F, et al. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev. 2008 Jan 23;(1):Cd006264. PubMed PMID: 18254098; eng. DOI:10.1002/14651858.CD006264.pub2
   PubMed Web of Science ®Google Scholar
• Miskiewicz P, Kryczka A, Ambroziak U, et al. Is high dose intravenous methylprednisolone pulse therapy in patients with graves’ orbitopathy safe? Endokrynol Pol. 2014;65(5):402–413. PubMed PMID: 25301492; eng.
   PubMed Web of Science ®Google Scholar
• Gao J, Feng S, Wang J, et al. Prolonged methylprednisolone therapy after the pulse treatment for patients with moderate-to-severe paraquat poisoning: A retrospective analysis. Medicine (Baltimore). 2017 Jun;96(25):e7244. PubMed PMID: 28640126; PubMed Central PMCID: PMCPMC5484234. eng.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mishra D, Kurien S, et al. Primary treatment of kawasaki disease with corticosteroids. J Clin Diagn Res. 2014 May;8(5):Pd04–5. PubMed PMID: 24995226; PubMed Central PMCID: PMCPMC4080047. eng.
   PubMedGoogle Scholar
• Patel RM, Shulman ST. Kawasaki disease: a comprehensive review of treatment options. J Clin Pharm Ther. 2015 Dec;40(6):620–625. PubMed PMID: 26547265; eng.
   PubMed Web of Science ®Google Scholar
• Yu JJ. Use of corticosteroids during acute phase of Kawasaki disease. World J Clin Pediatr. 2015 Nov 8;4(4):135–142. PubMed PMID: 26566486; PubMed Central PMCID: PMCPMC4637804. eng.
   PubMedGoogle Scholar
• Kuo HC, Yang KD, Chang WC, et al. Kawasaki disease: an update on diagnosis and treatment. Pediatr Neonatol. 2012 Feb;53(1):4–11. PubMed PMID: 22348488; eng.
   PubMed Web of Science ®Google Scholar
• Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003 Jun;142(6):611–616. PubMed PMID: 12838187; eng.
   PubMed Web of Science ®Google Scholar
• Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007 Feb 15;356(7):663–675. PubMed PMID: 17301297; eng.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012 Apr 28;379(9826):1613–1620. PubMed PMID: 22405251; eng.
   PubMed Web of Science ®Google Scholar
• Miyata K, Kaneko T, Morikawa Y, et al. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (post RAISE): a multicentre, prospective cohort study. Lancet Child Adolesc Health. 2018 Dec;2(12):855–862. PubMed PMID: 30337183; eng.
   PubMedGoogle Scholar
• Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. Pediatrics. 2005 Oct;116(4):989–995. PubMed PMID: 16199713; eng.
   PubMed Web of Science ®Google Scholar
• Athappan G, Gale S, Ponniah T. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature. Cardiovasc J Afr. 2009 Jul-Aug;20(4):233–236. PubMed PMID: 19701534; PubMed Central PMCID: PMCPMC3734755. eng.
   PubMed Web of Science ®Google Scholar
• Zhu BH, Lv HT, Sun L, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr. 2012 Mar;171(3):571–578. PubMed PMID: 22057683; PubMed Central PMCID: PMCPMC3284666. eng.
   PubMed Web of Science ®Google Scholar
• Yang X, Liu G, Huang Y, et al. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease. Cardiol Young. 2015 Aug;25(6):1182–1190. PubMed PMID: 25597708; eng.
   PubMedGoogle Scholar
• Chen S, Dong Y, Kiuchi MG, et al. Coronary artery complication in Kawasaki disease and the importance of early intervention: a systematic review and meta-analysis. JAMA Pediatr. 2016 Dec 1;170(12):1156–1163. PubMed PMID: 27749951; eng.
   PubMed Web of Science ®Google Scholar
• Wardle AJ, Connolly GM, Seager MJ, et al. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017 Jan 27;1:Cd011188. PubMed PMID: 28129459; PubMed Central PMCID: PMCPMC6464937. eng.
   PubMedGoogle Scholar
• Yang TJ, Lin MT, Lu CY, et al. The prevention of coronary arterial abnormalities in Kawasaki disease: a meta-analysis of the corticosteroid effectiveness. J Microbiol Immunol Infect. 2018 Jun;51(3):321–331. PubMed PMID: 28927685; eng.
   PubMedGoogle Scholar
• Chan H, Chi H, You H, et al. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease. BMC Pediatr. 2019 May 17;19(1):158. PubMed PMID: 31101091; PubMed Central PMCID: PMCPMC6524334. eng.
   PubMedGoogle Scholar
• Joshi M, Tulloh R. Kawasaki disease and coronary artery aneurysms: from childhood to adulthood. Future Cardiol. 2017 Aug 22;13:491–501.
   Web of Science ®Google Scholar
• Dhanrajani A, Yeung RSM. Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease. Curr Opin Rheumatol. 2017 Sep;29(5):547–552. PubMed PMID: 28661936; eng.
   PubMed Web of Science ®Google Scholar
• Weng KP, Ou SF, Lin CC, et al. Recent advances in the treatment of Kawasaki disease. J Chin Med Assoc. 2011 Nov;74(11):481–484. PubMed PMID: 22100015; eng.
   PubMed Web of Science ®Google Scholar
• Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther. 2010 Feb;8(2):197–203. PubMed PMID: 20109049; PubMed Central PMCID: PMCPMC2845298. eng.
   PubMed Web of Science ®Google Scholar
• Gedalia A. Kawasaki disease: 40 years after the original report. Curr Rheumatol Rep. 2007 Aug;9(4):336–341. PubMed PMID: 17688844; eng.
   PubMed Web of Science ®Google Scholar
• Sano S, Nakagawa Y, Iwashima S, et al. Dynamics of endogenous glucocorticoid secretion and its metabolism in Kawasaki disease. Steroids. 2010 Dec;75(12):848–852. PubMed PMID: 20600204; eng.
   PubMed Web of Science ®Google Scholar
• Zhao CN, Du ZD, Gao LL. corticosteroid therapy might be associated with the development of coronary aneurysm in children with Kawasaki disease. Chin Med J (Engl). 2016 Apr 20;129(8):922–928. PubMed PMID: 27064036; PubMed Central PMCID: PMCPMC4831526. eng.
   PubMed Web of Science ®Google Scholar
• Sudo D, Nakamura Y. Nationwide surveys show that the incidence of recurrent Kawasaki disease in Japan has hardly changed over the last 30 years. Acta Paediatrica. 2017 May;106(5):796–800. PubMed PMID: 28164356; eng.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang Z, Liu S, et al. Epidemiologic survey of Kawasaki disease in Jilin from 1999 through 2008. Pediatr Cardiol. 2012 Feb;33(2):272–279. PubMed PMID: 21965088; PubMed Central PMCID: PMCPMC3264881. eng.
   PubMed Web of Science ®Google Scholar
• Baek JY, Song MS. Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. Korean J Pediatr. 2016 Feb;59(2):80–90. PubMed PMID: 26958067; PubMed Central PMCID: PMCPMC4781736. eng.
   PubMedGoogle Scholar
• Li X, Chen Y, Tang Y, et al. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases. Eur J Pediatr. 2018 Aug;177(8):1279–1292. PubMed PMID: 29948255; PubMed Central PMCID: PMCPMC6061038. eng.
   PubMed Web of Science ®Google Scholar
• Liu L, Yin W, Wang R, et al. The prognostic role of abnormal liver function in IVIG unresponsiveness in Kawasaki disease: a meta-analysis. Inflammation Res. 2016 Feb;65(2):161–168. PubMed PMID: 26645912; eng.
   PubMed Web of Science ®Google Scholar
• Ogata S, Ogihara Y, Honda T, et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012 Jan;129(1):e17–23. PubMed PMID: 22144699; eng.
   PubMed Web of Science ®Google Scholar
• Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011 May;158(5):831–835.e3. PubMed PMID: 21168857; PubMed Central PMCID: PMCPMC3075321. eng.
   PubMed Web of Science ®Google Scholar
• Fabi M, Andreozzi L, Corinaldesi E, et al. Inability of Asian risk scoring systems to predict intravenous immunoglobulin resistance and coronary lesions in Kawasaki disease in an Italian cohort. Eur J Pediatr. 2019 Mar;178(3):315–322. PubMed PMID: 30499051; eng.
   PubMed Web of Science ®Google Scholar
• Arane K, Mendelsohn K, Mimouni M, et al. Japanese scoring systems to predict resistance to intravenous immunoglobulin in Kawasaki disease were unreliable for Caucasian Israeli children. Acta Paediatrica. 2018 Dec;107(12):2179–2184. PubMed PMID: 29797463; eng.
   PubMed Web of Science ®Google Scholar
• Jakob A, von Kries R, Horstmann J, et al. Failure to predict high-risk Kawasaki disease patients in a population-based study cohort in Germany. Pediatr Infect Dis J. 2018 Sep;37(9):850–855. PubMed PMID: 29406464; eng.
   PubMed Web of Science ®Google Scholar
• Sanchez-Manubens J, Anton J, Bou R, et al. Role of the egami score to predict immunoglobulin resistance in Kawasaki disease among a Western mediterranean population. Rheumatol Int. 2016 Jul;36(7):905–910. PubMed PMID: 27215220; eng.
   PubMed Web of Science ®Google Scholar
• Son MBF, Gauvreau K, Tremoulet AH, et al. Risk model development and validation for prediction of coronary artery aneurysms in Kawasaki disease in a North American population. J Am Heart Assoc. 2019 Jun 4;8(11):e011319. PubMed PMID: 31130036; PubMed Central PMCID: PMCPMC6585355. eng.
   PubMed Web of Science ®Google Scholar
• Tan XH, Zhang XW, Wang XY, et al. A new model for predicting intravenous immunoglobin-resistant Kawasaki disease in Chongqing: A retrospective study on 5277 patients. Sci Rep. 2019 Feb 11;9(1):1722. PubMed PMID: 30742060; PubMed Central PMCID: PMCPMC6370794. eng.
   PubMedGoogle Scholar
• Takeshita S, Kanai T, Kawamura Y, et al. A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease. PloS One. 2017;12(5):e0176957. PubMed PMID: 28542183; PubMed Central PMCID: PMCPMC5441585. eng.
   PubMed Web of Science ®Google Scholar
• Evard F, Neumann V, Hopkins R, et al. Pulsed methylprednisolone therapy in rheumatoid arthritis. Ann Rheum Dis. 1991 Jan;50(1):66. PubMed PMID: 1994875; PubMed Central PMCID: PMCPMC1004332. eng.
   PubMed Web of Science ®Google Scholar
• Smith MD, Ahern MJ, Roberts-Thomson PJ. Pulse methylprednisolone therapy in rheumatoid arthritis: unproved therapy, unjustified therapy, or effective adjunctive treatment? Ann Rheum Dis. 1990 Apr;49(4):265–267. PubMed PMID: 2187419; PubMed Central PMCID: PMCPMC1004053. eng.
   PubMed Web of Science ®Google Scholar
• Kijima Y, Kamiya T, Suzuki A, et al. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ J. 1982 Nov;46(11):1239–1242. PubMed PMID: 7131714; eng.
   PubMedGoogle Scholar
• Son MB, Newburger JW. Management of Kawasaki disease: corticosteroids revisited. Lancet. 2012 Apr 28;379(9826):1571–1572. PubMed PMID: 22405252; eng.
   PubMed Web of Science ®Google Scholar
• Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996 Jan;128(1):146–149. PubMed PMID: 8551407; eng.
   PubMed Web of Science ®Google Scholar
• Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child. 2005 Oct;90(10):1096–1097. PubMed PMID: 16177169; PubMed Central PMCID: PMCPMC1720131. eng.
   PubMed Web of Science ®Google Scholar
• Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008 Feb;93(2):142–146. PubMed PMID: 17962370; eng.
   PubMed Web of Science ®Google Scholar
• Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol. 2009 Feb;53(1):15–19. PubMed PMID: 19167633; eng.
   PubMed Web of Science ®Google Scholar
• Teraguchi M, Ogino H, Yoshimura K, et al. Steroid pulse therapy for children with intravenous immunoglobulin therapy-resistant Kawasaki disease: a prospective study. Pediatr Cardiol. 2013 Apr;34(4):959–963. PubMed PMID: 23184018; eng.
   PubMed Web of Science ®Google Scholar
• Singh S, Sharma A, Jiao F. Kawasaki disease: Issues in diagnosis and treatment–a developing country perspective. Indian J Pediatr. 2016 Feb;83(2):140–145. PubMed PMID: 26400032; eng.
   PubMed Web of Science ®Google Scholar
• Ghimire LV, Chou FS, Mahotra NB, et al. An update on the epidemiology, length of stay, and cost of Kawasaki disease hospitalisation in the United States. Cardiol Young. 2019 Jun;29(6):828–832. PubMed PMID: 31169101; eng.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kobayashi T, Morikawa A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr. 2013 Aug;163(2):521–526. PubMed PMID: 23485027; eng.
   PubMed Web of Science ®Google Scholar
• Jibiki T, Kato I, Shiohama T, et al. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease. Pediatrics International. 2011 Oct;53(5):729–735. PubMed PMID: 21342358; eng.
   PubMed Web of Science ®Google Scholar
• Marginean CO, Melit LE, Gozar L, et al. Incomplete refractory Kawasaki disease in an infant-a case report and a review of the literature. Front Pediatr. 2018;6:210. PubMed PMID: 30101141; PubMed Central PMCID: PMCPMC6074057. eng.
   PubMed Web of Science ®Google Scholar
• Okubo Y, Michihata N, Morisaki N, et al. Association between dose of glucocorticoids and coronary artery lesions in Kawasaki disease. Arthritis Care Res (Hoboken). 2018 Jul;70(7):1052–1057. PubMed PMID: 29073349; eng.
   PubMed Web of Science ®Google Scholar
• Taddio A, Rossi ED, Monasta L, et al. Describing Kawasaki shock syndrome: results from a retrospective study and literature review. Clin Rheumatol. 2017 Jan;36(1):223–228. PubMed PMID: 27230223; eng.
   PubMed Web of Science ®Google Scholar
• Lin Y, Shi L, Deng YJ, et al. Kawasaki disease shock syndrome complicated with macrophage activation syndrome in a 5-month old boy: A case report. Medicine (Baltimore). 2019 Jan;98(4):e14203. PubMed PMID: 30681594; PubMed Central PMCID: PMCPMC6358384. eng.
   PubMed Web of Science ®Google Scholar
• Tissandier C, Lang M, Lusson JR, et al. Kawasaki shock syndrome complicating a recurrence of Kawasaki disease. Pediatrics. 2014 Dec;134(6):e1695–9. PubMed PMID: 25384485; eng.
   PubMed Web of Science ®Google Scholar
• Hendricks M, Pillay S, Davidson A, et al. Kawasaki disease preceding haemophagocytic lymphohistiocytosis: challenges for developing world practitioners. Pediatr Blood Cancer. 2010 Jul 1;54(7):1023–1025. PubMed PMID: 20135702; eng.
   PubMed Web of Science ®Google Scholar
• Dominguez SR, Friedman K, Seewald R, et al. Kawasaki disease in a pediatric intensive care unit: a case-control study. Pediatrics. 2008 Oct;122(4):e786–90. PubMed PMID: 18809597; eng.
   PubMed Web of Science ®Google Scholar
• Novo A, Pinto S, Prior AC, et al. Kawasaki disease and sensorineural hearing loss: an (un)expected complication. Eur J Pediatr. 2012 May;171(5):851–854. PubMed PMID: 22227968; eng.
   PubMed Web of Science ®Google Scholar
• Stowe RC. Facial nerve palsy, Kawasaki disease, and coronary artery aneurysm. Eur J Paediatric Neurol. 2015 Sep;19(5):607–609. PubMed PMID: 26101056; eng.
   PubMed Web of Science ®Google Scholar
• Thakkar D, Radhakrishnan N, Pruthi PK, et al. Kawasaki disease with autoimmune hemolytic anemia. Indian Pediatr. 2015 Mar 8;52(3):245–246. PubMed PMID: 25849007; eng.
   PubMed Web of Science ®Google Scholar
• Micallef ES, Attard MS, Grech V. A case of atypical Kawasaki disease with giant coronary artery aneurysm containing thrombus. Images Paediatr Cardiol. 2016 Jul-Sep;18(3):9–15. PubMed PMID: 28405208; PubMed Central PMCID: PMCPMC5270204. eng.
   PubMedGoogle Scholar
• Sato T, Somura J, Maruo Y. Steroid pulse therapy for Kawasaki disease complicated with myocarditis. Indian Pediatr. 2016 Nov 15;53(11):1015–1016. PubMed PMID: 27889733; eng.
   PubMed Web of Science ®Google Scholar
• Suga K, Inoue M, Ono A, et al. Early combined treatment with steroid and immunoglobulin is effective for serious Kawasaki disease complicated by myocarditis and encephalopathy. J Med Invest. 2016;63(1–2):140–143. PubMed PMID: 27040070; eng.
   PubMedGoogle Scholar
• Mitani M, Ehara K, Araki K, et al. Encephalopathy and pancreatitis in a 3-year-old girl with Kawasaki disease. Pediatrics International. 2017 Apr;59(4):496–498. PubMed PMID: 28401742; eng.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wan H, Du M, et al. Capillary leak syndrome and aseptic meningitis in a patient with Kawasaki disease: A case report. Medicine (Baltimore). 2018 Jun;97(23):e10716. PubMed PMID: 29879013; PubMed Central PMCID: PMCPMC5999480. eng.
   PubMed Web of Science ®Google Scholar
• Aggarwal V, Etinger V, Orjuela AF. Sensorineural hearing loss in Kawasaki disease. Ann Pediatr Cardiol. 2016 Jan-Apr;9(1):87–89. PubMed PMID: 27011703; PubMed Central PMCID: PMCPMC4782479. eng.
   PubMed Web of Science ®Google Scholar
• Kim NY, Choi DY, Jung MJ, et al. A case of refractory Kawasaki disease complicated by peripheral ischemia. Pediatr Cardiol. 2008 Nov;29(6):1110–1114. PubMed PMID: 18481137; eng.
   PubMed Web of Science ®Google Scholar
• Dahlem PG, von Rosenstiel IA, Lam J, et al. Pulse methylprednisolone therapy for impending cardiac tamponade in immunoglobulin-resistant Kawasaki disease. Intensive Care Med. 1999 Oct;25(10):1137–1139. PubMed PMID: 10551972; eng.
   PubMed Web of Science ®Google Scholar
• Shetty AK, Homsi O, Ward K, et al. Massive lymphadenopathy and airway obstruction in a child with Kawasaki disease: success with pulse steroid therapy. J Rheumatol. 1998 Jun;25(6):1215–1217. PubMed PMID: 9632089; eng.
   PubMed Web of Science ®Google Scholar
• Lim TC, Yeo WS, Loke KY, et al. Bilateral facial nerve palsy in Kawasaki disease. Ann Acad Med Singapore. 2009 Aug;38(8):737–738. PubMed PMID: 19736583; eng.
   PubMed Web of Science ®Google Scholar
• Maggio MC, Cimaz R, Alaimo A, et al. Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings. J Med Case Rep. 2019 Apr 24;13(1):104. PubMed PMID: 31014402; PubMed Central PMCID: PMCPMC6480815. eng.
   PubMedGoogle Scholar
• Adachi S, Sakaguchi H, Kuwahara T, et al. High regression rate of coronary aneurysms developed in patients with immune globulin-resistant Kawasaki disease treated with steroid pulse therapy. Tohoku J Exp Med. 2010 Apr;220(4):285–290. PubMed PMID: 20410679; eng.
   PubMed Web of Science ®Google Scholar
• Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–465. PubMed PMID: 26789102; eng.
   PubMed Web of Science ®Google Scholar
• Ebato T, Ogata S, Ogihara Y, et al. The clinical utility and safety of a new strategy for the treatment of refractory Kawasaki disease. J Pediatr. 2017 Dec;191:140–144. PubMed PMID: 29173297; eng.
   PubMed Web of Science ®Google Scholar
• Nagakura A, Morikawa Y, Sakakibara H, et al. Bradycardia associated with prednisolone in children with severe Kawasaki disease. J Pediatr. 2017 Jun;185:106–111.e1. PubMed PMID: 28343657; eng.
   PubMed Web of Science ®Google Scholar
• Tervaert JW. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol. 2009 Jun;156(3):377–385. PubMed PMID: 19309350; PubMed Central PMCID: PMCPMC2691964. eng.
   PubMed Web of Science ®Google Scholar
• Chang LS, Lee HC, Tsai YC, et al. Decreased incidence of glaucoma in children with asthma using inhaled corticosteroid: a cohort study. Oncotarget. 2017 Dec 1;8(62):105463–105471. PubMed PMID: 29285264; PubMed Central PMCID: PMCPMC5739651. eng.
   PubMedGoogle Scholar
• Goto M, Miyagawa N, Kikunaga K, et al. High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone. Endocr J. 2015;62(2):145–151. PubMed PMID: 25342092; eng.
   PubMed Web of Science ®Google Scholar
• Goto M, Miyagawa N, Kikunaga K, et al. Single serum cortisol values at 09:00 h can be indices of adrenocortical function in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone. Clinical Pediatric Endocrinology. 2015 Jul;24(3):69–75. PubMed PMID: 26594091; PubMed Central PMCID: PMCPMC4639530. eng.
   Google Scholar
• Chen HH, Liu PM, Bong CN, et al. Methylprednisolone pulse therapy for massive lymphadenopathy in a child with intravenous immunoglobulin-resistant Kawasaki disease. J Microbiol Immunol Infect. 2005 Apr;38(2):149–152. PubMed PMID: 15843862; eng.
   PubMedGoogle Scholar
• Qian W, Tang Y, Yan W, et al. A comparison of efficacy of six prediction models for intravenous immunoglobulin resistance in Kawasaki disease. Ital J Pediatr. 2018 Mar 9;44(1):33. PubMed PMID: 29523168; PubMed Central PMCID: PMCPMC5845199. eng.
   PubMedGoogle Scholar
• Rigante D, Andreozzi L, Fastiggi M, et al. Critical overview of the risk scoring systems to predict non-responsiveness to intravenous immunoglobulin in Kawasaki syndrome. Int J Mol Sci. 2016 Feb 24;17(3):278. PubMed PMID: 26927060; PubMed Central PMCID: PMCPMC4813142. eng.
   PubMed Web of Science ®Google Scholar
• Lin MT, Chang CH, Sun LC, et al. Risk factors and derived formosa score for intravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease. J Formos Med Assoc. 2016 May;115(5):350–355. PubMed PMID: 25910931; eng.
   PubMed Web of Science ®Google Scholar